Entera Bio (ENTX) Non-Current Assets (2017 - 2026)
Entera Bio's (ENTX) quarterly Non-Current Assets came in at $636000.0 in Q1 2026, up 66.49% YoY from $382000.0 in Q1 2025, and down 8.49% on a QoQ basis from $695000.0 in Q4 2025.
Entera Bio (ENTX) Non-Current Assets (2017 - 2026) Analysis & Trends
Entera Bio (ENTX) has 10 years of Non-Current Assets data on file, last reported at $636000.0 in Q1 2026.
- Quarterly Non-Current Assets rose 66.49% year-over-year to $636000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $636000.0 (up 66.49% YoY) and the FY2025 annual result came in at $695000.0, up 66.27% from the prior year.
- Non-Current Assets eased to $636000.0 in Q1 2026, from $695000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $695000.0 in Q4 2025 to a low of $233000.0 in Q1 2023.
- A 5-year average of $476352.9 and a median of $440000.0 in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets tumbled 65.28% — and 2024, when it surged 109.44%.
- Tracing ENTX's Non-Current Assets over 5 years: stood at $278000.0 in 2022, then surged by 82.73% to $508000.0 in 2023, then dropped by 17.72% to $418000.0 in 2024, then surged by 66.27% to $695000.0 in 2025, then fell by 8.49% to $636000.0 in 2026.
- The last three Non-Current Assets figures came in at $636000.0 (Q1 2026), $695000.0 (Q4 2025), and $400000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | 584,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 584,000.00 |
| Mar 31, 2026 | 636,000.00 |
| Dec 31, 2025 | 695,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 356,000.00 |
| Mar 31, 2025 | 382,000.00 |
| Dec 31, 2024 | 418,000.00 |
| Sep 30, 2024 | 401,000.00 |
| Jun 30, 2024 | 440,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Dec 31, 2023 | 508,000.00 |
| Sep 30, 2023 | 549,000.00 |
| Jun 30, 2023 | 631,000.00 |
| Mar 31, 2023 | 233,000.00 |
| Dec 31, 2022 | 278,000.00 |
| Sep 30, 2022 | 350,000.00 |
| Jun 30, 2022 | 662,000.00 |
| Mar 31, 2022 | 671,000.00 |
| Dec 31, 2021 | 658,000.00 |
| Jun 30, 2021 | 1.03 Mn |